- Home
- ARHS vs XERS Comparison
ARHS vs XERS Comparison
Compare ARHS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- XERS
- Stock Information
- Founded
- ARHS 1986
- XERS 2005
- Country
- ARHS United States
- XERS United States
- Employees
- ARHS N/A
- XERS N/A
- Industry
- ARHS Other Specialty Stores
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- XERS Health Care
- Exchange
- ARHS Nasdaq
- XERS Nasdaq
- Market Cap
- ARHS 1.3B
- XERS 1.3B
- IPO Year
- ARHS 2021
- XERS 2018
- Fundamental
- Price
- ARHS $11.73
- XERS $7.83
- Analyst Decision
- ARHS Buy
- XERS Strong Buy
- Analyst Count
- ARHS 13
- XERS 7
- Target Price
- ARHS $11.71
- XERS $8.00
- AVG Volume (30 Days)
- ARHS 2.4M
- XERS 3.5M
- Earning Date
- ARHS 08-07-2025
- XERS 08-07-2025
- Dividend Yield
- ARHS N/A
- XERS N/A
- EPS Growth
- ARHS N/A
- XERS N/A
- EPS
- ARHS 0.50
- XERS N/A
- Revenue
- ARHS $1,335,951,000.00
- XERS $246,025,000.00
- Revenue This Year
- ARHS $8.41
- XERS $43.89
- Revenue Next Year
- ARHS $7.04
- XERS $20.40
- P/E Ratio
- ARHS $23.46
- XERS N/A
- Revenue Growth
- ARHS 4.76
- XERS 35.62
- 52 Week Low
- ARHS $6.61
- XERS $2.48
- 52 Week High
- ARHS $13.97
- XERS $8.02
- Technical
- Relative Strength Index (RSI)
- ARHS 55.80
- XERS 75.74
- Support Level
- ARHS $11.54
- XERS $7.27
- Resistance Level
- ARHS $12.14
- XERS $8.02
- Average True Range (ATR)
- ARHS 0.48
- XERS 0.29
- MACD
- ARHS -0.13
- XERS -0.00
- Stochastic Oscillator
- ARHS 24.29
- XERS 79.35
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).